Loading clinical trials...
Loading clinical trials...
A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
Conditions
Interventions
Upadacitinib
Dupilumab
+2 more
Locations
159
United States
Clinical Research Center AL /ID# 210277
Birmingham, Alabama, United States
University of Arkansas for Medical Sciences /ID# 211688
Little Rock, Arkansas, United States
Tien Q Nguyen MD, Inc /ID# 208934
Fountain Valley, California, United States
UCSF Fresno /ID# 213253
Fresno, California, United States
Jonathan Corren, MD. INC /ID# 208987
Los Angeles, California, United States
California Allergy and Asthma Medical Group /ID# 213680
Los Angeles, California, United States
Start Date
February 21, 2019
Primary Completion Date
August 27, 2020
Completion Date
December 9, 2020
Last Updated
March 15, 2024
NCT07262983
NCT06389136
NCT06342713
NCT07223697
NCT07290803
NCT07265479
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions